Paper Details

  1. Home
  2. Paper Details

Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.

Author: AhnenDennis J, AlbersC Gregory, CarpenterPhilip M, Fujikawa-BrooksSharon, GernerEugene W, GillenDaniel L, GoldschmidSteven, HagedornCurt H, HawkErnest, KelloffGary, KidaoJayashri, LancePeter, LawsonMichael J, McCrackenJohn, McLarenChristine E, MeyskensFrank L, PelotDaniel, TurgeonD Kim

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

This study evaluated the efficacy of a combination of difluoromethylornithine (DFMO) and sulindac in preventing colorectal adenoma recurrence. The combination therapy significantly reduced the recurrence of adenomas, including advanced adenomas, with minimal side effects.
Paper Details　
Original Abstract of the Article :
Preclinical studies of chemoprevention drugs given in combination at low doses show remarkable efficacy in preventing adenomas with little additional toxicities, suggesting a strategy to improve risk to benefit ratios for preventing recurrent adenomas. Three hundred seventy-five patients with histor...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/18841250

データ提供：米国国立医学図書館（NLM）

Preventing Colorectal Adenomas: A Dual-Drug Approach

This research focuses on colorectal adenomas, precancerous growths in the colon. The authors investigate the potential of a combination therapy, consisting of difluoromethylornithine (DFMO) and sulindac, to prevent the recurrence of these adenomas. They conducted a randomized, placebo-controlled trial to evaluate the effectiveness of this combination therapy in a group of patients with a history of resected adenomas.

A Promising Partnership: DFMO and Sulindac in Action

The researchers found that the combination therapy of DFMO and sulindac significantly reduced the recurrence of colorectal adenomas compared to placebo. They observed a 41.1% recurrence rate in the placebo group compared to 12.3% in the combination therapy group. The study also showed a significant reduction in the recurrence of advanced adenomas. This demonstrates the potential of this combination therapy in preventing the progression of adenomas into cancer.

A Beacon of Hope: Preventing Colorectal Cancer

This research provides promising evidence for the potential of DFMO and sulindac in preventing colorectal adenomas, thereby reducing the risk of colorectal cancer. It's like finding a hidden oasis in the desert of cancer prevention, offering a potential way to reduce the risk of this devastating disease. This study underscores the importance of ongoing research to identify effective chemoprevention strategies.

Dr.Camel's Conclusion

Colorectal adenomas are like hidden sandstorms in the desert of our bodies – they can silently emerge and escalate into serious health risks. This study provides a promising path towards preventing these sandstorms, demonstrating the potential of DFMO and sulindac to protect against this silent threat.

Date :
  1. Date Completed 2009-03-05
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

18841250

DOI: Digital Object Identifier

NIHMS58572

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.